Merck acquires IOmet Pharma
Expanding immuno-oncology development program
13-Jan-2016 -
Merck announced that it has acquired IOmet, a privately-held UK-based drug discovery company focused on the development of innovative medicines for the treatment of cancer, with a particular emphasis on the fields of cancer immunotherapy and cancer metabolism. Under terms of the agreement, Merck, ...
acquisitions
drug discovery
MSD